Logo image
Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in Abdominal Aortic Aneurysm: A Randomized Controlled Trial
Journal article   Open access   Peer reviewed

Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in Abdominal Aortic Aneurysm: A Randomized Controlled Trial

Lara Meital, Karl Schulze, Rebecca Magee, Jill O'Donnell, Pankaj Jha, Chaim Y Meital, Rebecca Donkin, Tom G Bailey, Christopher Askew and Fraser Russell
Nutrients, Vol.13(1), pp.1-9
2021
PMCID: PMC7824679
PMID: 33396567
pdf
Long Chain Omega-3 Polyunsaturated Fatty Acids Improve Vascular Stiffness in Abdominal Aortic Aneurysm - A Randomized Controlled Trial369.00 kBDownloadView
Published Version Open Access CC BY V4.0
url
https://doi.org/10.3390/nu13010138View
Published Version

Abstract

abdominal aortic aneurysm pulse wave velocity vascular stiffness long chain omega- 3 polyunsaturated fatty acids
Abdominal aortic aneurysm (AAA) is a vascular disease involving permanent focal dila-tion of the abdominal aorta (≥30 mm) that can lead to catastrophic rupture. Destructive remodeling of aortic connective tissue in AAA contributes to wall stiffening, a mechanical parameter of the arterial system linked to a heightened risk of cardiovascular morbidity and mortality. Since aortic stiffening is associated with AAA progression, treatment options that target vascular inflammation would appear prudent. Given this, and growing evidence indicating robust anti-inflammatory and vasoprotective properties for long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs), this study evaluated the impact of these nutrients (1.8 g/day for 12 weeks) on indices of vascular stiffness in patients with AAA. At baseline, pulse wave velocity (PWV) and augmentation index normalized to a heart rate of 75 bpm (AIx75) were significantly higher in patients with AAA compared to control participants (PWV: 14.2 ± 0.4 m.s −1 vs. 12.6 ± 0.4 m.s −1 , p = 0.014; AIx75: 26.4 ± 1.7% vs. 17.3 ± 2.7%, p = 0.005). Twelve-week LC n-3 PUFA supplementation significantly decreased PWV (baseline: 14.2 ± 0.6 m.s −1 , week 12: 12.8 ± 0.7 m.s −1 , p = 0.014) and heart rate (baseline: 63 ± 3 bpm, week 12: 58 ± 3 bpm, p = 0.009) in patients with AAA. No change was observed for patients receiving placebo capsules. While this raises the possibility that LC n-3 PUFAs provide improvements in aortic stiffness in patients with AAA, the clinical implications remain to be fully elucidated.

Details

Metrics

15 File views/ downloads
77 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
Web Of Science research areas
Nutrition & Dietetics

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: SDGs from InCites

Logo image